Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
about
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responsesGenetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencingLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trChronic Myelogenous Leukemia, Version 1.2014Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptorImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.Suboptimal responses in chronic myeloid leukemia: implications and management strategiesRationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.The detection and significance of minimal residual disease in acute and chronic leukemia.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.How I monitor residual disease in chronic myeloid leukemia.Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesMonitoring molecular response in chronic myeloid leukemiaSuboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitorsTailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.Molecular resistance: an early indicator for treatment change?Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.Molecular monitoring.Response-related predictors of survival in CML.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotiniImportance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance.Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods.Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients.Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute.Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
P2860
Q28475717-94ACD5D6-F784-4D69-9B70-1846E26B3C8BQ28534967-49DCA66E-05A5-4BD4-8D75-21E6C826D142Q31033077-EA52353C-D1DF-4AD3-8148-225506C114FAQ34522810-9836B025-9425-4E3D-BD1D-A6C0E5AFD929Q35483727-3E5F352C-71D1-4C31-BC81-04F22CBC1EE7Q35816396-1A35CCC5-5FA9-4346-8FCC-D248ADE981F9Q35849671-34F90162-395E-4925-B0F7-26EA7759DD69Q36144079-D1AA243C-7C48-4331-B751-1A9DE179889EQ36600934-6ED7151E-38CE-4653-A37F-32502D5F36C7Q36648048-A67AA4ED-15D3-4021-8757-6CFE2348C692Q36734508-78B9514E-AEDE-4496-BC8D-2C7F90D1A02CQ36846361-08463653-F0C3-49B4-BF36-3A678527EA10Q37013074-4653A335-4404-4075-94CF-9E9EE542FF1DQ37059746-E6B6AAF5-E437-4FE9-810E-5DFAB6246C79Q37095355-ADD13BD5-A320-42CC-A314-17CE56DEA90EQ37143280-1F824E05-1F4F-4614-9ABA-333378BB98F4Q37148391-A0D5EE9D-CF70-4228-8EAC-F6DC10D62FA1Q37361209-FD388AA0-AFF3-4FB1-B274-CAE08C68B8E5Q37428659-AB8E694B-245B-4109-AF77-F426851D997BQ37545067-373F1CC6-985E-439D-8505-61F667CA9EB5Q37810110-B61F7DCB-E10A-4F39-994B-21D1FFD9076DQ37877650-CE95D65F-94E3-47E7-B1B1-DCFBE7FD51A6Q37979587-9D769049-2BB3-434B-ADD0-F7FD33709EC1Q38154622-3844445C-F091-426E-B93A-6C06BF3AB090Q38176284-B0538367-2053-42E6-AFF2-0884DBD4898BQ38392705-88FC98EE-5D3D-495B-B27A-163C975A9B5CQ39285841-249D72E2-48CE-458E-90A4-6D6D6D9CE771Q39350678-A488B9ED-94D7-438D-BCC8-4FE01D57FB17Q40095759-1EE202B5-4C2A-4A66-AB77-E54767E3D615Q40306743-FFCD94C9-1CDF-4C23-A827-EE94EF466523Q41594071-C6A90D99-1824-4234-850E-E88D44E5561FQ41768439-524778CC-4DE9-4509-8A17-DAF92367135CQ42409714-D5B2DEBD-27A1-4A54-97F7-F784C581BCA5Q43607483-55FE969C-ED02-428A-AD52-BA418B313262Q45043877-9849B14D-E013-4F7D-8450-56EBB1B9EF4CQ46426199-2A1F84E8-AF66-401E-B3D6-DD7A9CD07D87Q46947501-BFBC8A86-AE14-4A19-95FB-F328802A2874Q50118214-25F64692-CC0C-4A85-A4D3-AA0C71C35F4AQ50917057-CE622CC9-EE2F-4861-8782-571895BA1520Q53591515-58C729B6-1E3E-4642-9E25-B956A1C465B0
P2860
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Imatinib produces significantl ...... oid leukemia in chronic phase.
@en
Imatinib produces significantl ...... oid leukemia in chronic phase.
@nl
type
label
Imatinib produces significantl ...... oid leukemia in chronic phase.
@en
Imatinib produces significantl ...... oid leukemia in chronic phase.
@nl
prefLabel
Imatinib produces significantl ...... oid leukemia in chronic phase.
@en
Imatinib produces significantl ...... oid leukemia in chronic phase.
@nl
P2093
P2860
P356
P1433
P1476
Imatinib produces significantl ...... oid leukemia in chronic phase.
@en
P2093
Bradstock K
Branford S
Gathmann I
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403158
P577
2003-12-01T00:00:00Z